Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Ferring Pharmaceuticals A/S
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A study investigating a new treatment for patients with early septic shock
Show that the onset of action allows for FE 202158 to be used as primary vasopressor treatment in patients with vasodilatory hypotension in early septic shock.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
The PEACE Study: Investigating the Pharmacodynamics and Pharmacokinetics of FE 106483 Tablets in a Single Dose Study in Children with Nocturnal Enuresis. A Randomised, Double-Blind and Placebo-Controlled Study
To investigate the pharmacodynamic profile of 3 different dose levels of FE 106483 tablets in children with nocturnal enuresis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A randomised, double-blind, parallel groups, placebo-controlled, multi-centre study assessing the effects of a selective oxytocin antagonist (barusiban) and a mixed oxytocin antagonist – vasopressin V1a antagonist (atosiban) administered intravenously on luteal phase uterine contractions in oocyte donors supplemented with vaginal progesterone
To evaluate the effects of barusiban and atosiban compared to placebo on luteal phase uterine contractions in oocyte donors supplemented with progesterone
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
IPSS [ Time Frame: Three months after dosing ] [ Designated as safety issue: No ]
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Cancer Requiring Androgen Deprivation Therapy
•To demonstrate that degarelix is effective with respect to achieving and maintaining testosterone suppression to castrate levels, evaluated as the proportion of patients with testosterone suppression...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
Ferring Pharmaceuticals A/S
MAJ Il y a 5 ans
A randomised, controlled, assessor-blind, parallel groups, multinational, multicentre trial assessing the dose-response relationship of FE 999049 in controlled ovarian stimulation in women undergoing an assisted reproductive technology programme
To investigate the dose-response relationship of FE 999049 with respect to ovarian response in patients undergoing controlled ovarian stimulation
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4